CluenexJazz Pharmaceuticals JAZZ
Jazz Pharmaceuticals scores average on business quality (4.7 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Jazz Pharmaceuticals does
Jazz Pharmaceuticals develops and commercializes therapeutic products for neuroscience and oncology, generating $4.6B in revenue by treating patients with complex medical conditions through specialized prescription drugs.
- What it does best
Jazz turns scientific complexity into cash, delivering an 88.4% gross margin that sits in the top decile of its sector. This pricing power stems from entrenched specialty neuroscience treatments that doctors cannot easily substitute.
- The main risk
Heavy debt loads threaten financial flexibility, with total debt at $5.4B and a low interest coverage of 3.5x leaving little room for error if revenue growth stalls.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin sits at 19.4% alongside an FCF margin in the 90th percentile, proving the business converts top-line revenue into cash efficiently.
Proprietary neuroscience treatments lock in prescribing physicians and patients, supported by a gross margin in the sector's 93rd percentile.
Revenue grew 4.9% to reach $4.6B, continuing a steady multi-year expansion from $3.1B in 2021 but remaining in the bottom quartile of its sector.
Debt-to-equity sits at 1.2x with $2.4B in cash, while free cash flow reached $1.4B, showing solid cash generation despite heavy leverage.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on JAZZ
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Jazz Pharmaceuticals scores average on the Cluenex quality check (4.7 of 10), measured against its own industry. Profitability is strong, moat fair, growth slow and financial health weak.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 3, 2026.
See JAZZ today
- Today's verdict on JAZZ, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Jazz Pharmaceuticals (JAZZ)”, https://cluenex.com/stocks/jazz/, data as of Oct 10, 2026.